Metastatic mucinous ovarian cancer and treatment decisions based on histology and molecular markers rather than the primary location

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 10, Issue 9, 2012, Pages 1076-1080

  Jain, Angela ^a   Ryan, Paula D ^a   Seiden, Michael V ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BLEOMYCIN; CA 125 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LAPATINIB; MOLECULAR MARKER; OXALIPLATIN; TRASTUZUMAB;

ABDOMINAL PAIN; ADULT; APPENDECTOMY; ARTICLE; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER THERAPY; CASE REPORT; CLINICAL DECISION MAKING; COLLOID CARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; CYSTADENOCARCINOMA; DRUG WITHDRAWAL; FEMALE; GERM CELL TUMOR; HEADACHE; HISTOLOGY; HUMAN; HYPERSENSITIVITY; IMMUNOHISTOCHEMISTRY; LIVER BIOPSY; LYMPH NODE DISSECTION; LYMPHADENOPATHY; METASTASIS; NAUSEA; OMENTECTOMY; OVARY CANCER; SALPINGOOOPHORECTOMY;

EID: 84866535868     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2012.0113     Document Type: Article

References (25)

1. Vergote I, De Brabanter J, Fyles A, et al. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet 2001;357:176-182.
2. International Collaborative Ovarian Neoplasm Group. Paclitaxel plus carboplatin versus standard chemotherapy with either singleagent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON 3 randomised trial. Lancet 2002;360:505-515.
3. Hess V, A'Hern R, Nasiri N, et al. Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. J Clin Oncol 2004;22:1040-1044.
4. Morgan RJ, Alvarez RD, Armstrong DK, et al. NCCN Clinical Practice Guidelines in Oncology: Ovarian Cancer. Version 3, 2012. Available at: NCCN.org. Accessed July 26, 2012.
5. Harrison ML, Jameson C, Gore ME. Mucinous ovarian cancer. Int J Gynecol Cancer 2008;18:209-214.
6. McBroom JW, Parker MF, Krivak TC, et al. Primary appendiceal malignancy mimicking advanced stage ovarian carcinoma: a case series. Gynecol Oncol 2000;78:388-390.
7. Seidman JD, Kurman RJ, Ronnett BM. Primary and metastatic mucinous adenocarcinomas in the ovaries: incidence in routine practice with a new approach to improve intraoperative diagnosis. Am J Surg Pathol 2003;27:985-993.
8. Alexandre J, Ray-Coquard I, Selle F, et al. Mucinous advanced epithelial ovarian carcinoma: clinical presentation and sensitivity to platinum-paclitaxel- based chemotherapy, the GINECO experience. Ann Oncol 2010;21:2377-2381.
9. Heide I, Thiede C, Sonntag T, et al The status of p53 in the metastatic progression of colorectal cancer. Eur J Cancer 1997;33:1314-1322.
10. Lopez I, P Oliveira L, Tucci P, et al. Differrent mutation profiles associated to p53 accumulation in colorectal cancer. Gene 2012;499:81-87.
11. Munro AJ, Lain S, Lane DP. P53 abnormalities and outcomes in colorectal cancer: a systematic review. Br J Cancer 2005;92:434-444.
12. Cancer Genome Atlas Research Network. Integrated genomic analysis of ovarian carcinoma. Nature 2011;474:609-615.
13. Havrilesky L, Darcy M, Hamdan H, et al. Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2003;21:3814-3825.
14. Sato S, Itamochi H, Kigawa J, et al Combination chemotherapy of oxaliplatin and 5-fluorouracil may be an effective regimen for mucinous adenocarcinoma of the ovary: a potential treatment strategy. Cancer Sci 2008;100:546-551.
15. Di Fiore F, Blanchard F, Charbonnier F, et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. Br J Cancer 2007;96:1166-1169.
16. Amado RG, Wolf M, Peeters M, et al. Wild type kras status is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-1634.
17. Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408-1417.
18. Cuatrecasas M, Villaneuva A, Matias-Guiu X, Prat J. K-ras mutations in mucinous ovarian tumors. A clinicopathologic and molecular study in 95 cases. Cancer 1997;79:1581-1586.
19. Schilder RJ, Pathak HB, Lokshin AE, et al. Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash. Gyn Oncol 2009;113:21-27.
20. Li Q, Wang D, Li J, Chen P. Clinicopathological and prognostic significance of HER-2/neu and VEGF expression in colon carcinomas. BMC Cancer 2011;11:277.
21. Lee CH, Huntsman DG, Cheang MC, et al. Assessment of Her-1, Her-2, and Her-3 expression and Her-2 amplification in advanced stage ovarian carcinoma. Int J Gynec Pathol 2008;27:161-174.
22. Sorscher SM. Marked response to single agent trastuzumab in a patient with metastatic HER-2 gene amplified rectal cancer. Cancer Invest 2011;29:456-459.
23. McAlpine JN, Wiegand KC, Vang R, et al. HER-2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy. BMC Cancer 2009;9:433-444.
24. Blackwell KL, Burstein HJ, Storniolo AM, et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2010;28:1124-1130.
25. Shimizu Y, Umezawa S, Hasumi K, et al. A phase II study of combined CPT-11 and mitomycin-c in platinum refractory clear cell and mucinous ovarian carcinoma. Ann Acad Med Singapore 1998;27:650-656.